Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
Biden visits Houston to offer comfort after winter storm, tout vaccination efforts
FacebookTwitterEmail
1of11
President Joe Biden elbow bumps Joan Hessidence as he tours the Houston Food Bank Friday, Feb. 26, 2021 in Houston.Brett Coomer, Houston Chronicle / Staff photographerShow MoreShow Less
2of11
Houston SPCA volunteer and staff bringing out signs and adoptable puppies to welcome President Joe Biden as he is arrives at the Harris County Emergency Operations Center for a tour Friday, Feb. 26, 2021, in Houston.Yi-Chin Lee, Houston Chronicle / Staff photographerShow MoreShow Less
3of11
Andy Calixtro, 5, salutes as President Joe Biden s motorcade is leaving the Harris County Emergency Operations Center after a tour Friday, Feb. 26, 2021, in Houston. after a tour Friday, Feb. 26, 2021, in Houston.Yi-Chin Lee, Houston Chronicle / Staff photographerShow MoreShow Less
Mercy, Humana partner to expand access to virtual, value-based care
The health system and payer are joining forces to offer Medicare Advantage patients access to Mercy s telehealth center. They also plan to implement a value-based payment model, tying reimbursement for Mercy clinicians to care quality measures.
Shares0
On the heels of a coordinated care agreement with Anthem, St. Louis-based Mercy is partnering with another health insurer.
On Thursday, the health system announced it was entering into an agreement with Louisville, Kentucky-based Humana to expand patient access to virtual health resources.
Per the new agreement, Humana’s Medicare Advantage members who are patients at Mercy facilities and physician practices will gain in-network access to Mercy Virtual. Staffed with more than 300 clinicians, Mercy Virtual offers 24/7 telehealth services, including virtual primary care at home.
A new report from Kaufman Hall examines two potential financial situations for hospitals in 2021 one optimistic, and the other bleak. Hospitals could lose between $53 billion and $122 billion depending on which scenario plays out.
MedCity News
FDA approves Sarepta drug for muscular dystrophy with rare genetic mutation
The FDA decision gives Sarepta Therapeutics its third approved drug for Duchenne muscular dystrophy. The accelerated approval requires the biotech to conduct additional clinical testing to confirm the drug’s benefit.
Shares0
The FDA has approved a Sarepta Therapeutics drug for Duchenne muscular dystrophy, clearing the way for the company to commercialize its third therapy for the rare, muscle-wasting disease.
Thursday’s decision covers patients with a particular genetic mutation that affects an estimated 8% of Duchenne patients. The drug, casimersen, will be marketed under the name Amondys 45.